Chemomab Therapeutics Overview
- Year Founded
-
2011
- Status
-
Public
- Employees
-
12
- Stock Symbol
-
CMMB
- Investments
-
2
- Share Price
-
$1.56
- (As of Wednesday Closing)
Chemomab Therapeutics General Information
Description
Chemomab Therapeutics Ltd is a clinical-stage biotechnology company, focusing on the discovery and development of therapeutics for fibrosis-related diseases with large unmet needs. The company's candidate, CM-101, is a monoclonal antibody that targets CCL24 and was shown to interfere with the underlying biology of liver, skin, and lung fibrosis using a novel and differentiated mechanism of action. CM-101 has demonstrated the potential to treat multiple severe and life-threatening fibrotic and inflammatory diseases.
Contact Information
Website
www.chemomab.comCorporate Office
- 10 Habarzel Street, Building C, 10th Floor
- Tel Aviv 6971010
- Israel
Corporate Office
- 10 Habarzel Street, Building C, 10th Floor
- Tel Aviv 6971010
- Israel
Chemomab Therapeutics Stock Performance
As of 18-Nov-2026, Chemomab Therapeutics’s stock price is $1.56. Its current market cap is $12.5M with 8.05M shares.
(As of Wednesday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $1.56 | $1.64 | $0.92 - $2.99 | $12.5M | 8.05M | 103K | -$1.04 |
Chemomab Therapeutics Financials Summary
As of 30-Jun-2026, Chemomab Therapeutics has a trailing 12-month revenue of null.
|
In Thousands, USD |
TTM 30-Jun-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | 3,622 | 100 | 15,094 | (20,708) |
| Revenue | 0 | 0 | 0 | 0 |
| EBITDA | (7,851) | (9,497) | (14,686) | (25,392) |
| Net Income | (7,553) | (8,995) | (13,945) | (24,221) |
| Total Assets | 10,238 | 13,812 | 16,964 | 22,151 |
| Total Debt | 0 | 0 | 324 | 392 |
Chemomab Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Chemomab Therapeutics Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price |
% Owned |
|---|
Chemomab Therapeutics Patents
Chemomab Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| AU-2021259682-A1 | Method of treatment using anti-ccl24 antibody | Pending | 22-Apr-2020 | ||
| CA-3172627-A1 | Method of treatment using anti-ccl24 antibody | Pending | 22-Apr-2020 | ||
| EP-4139352-A1 | Method of treatment using anti-ccl24 antibody | Pending | 22-Apr-2020 | ||
| US-20230235037-A1 | Method of treatment using anti-ccl24 antibody | Pending | 22-Apr-2020 | ||
| WO-2021214759-A1 | Method of treatment using anti-ccl24 antibody | Inactive | 22-Apr-2020 | C07K16/24 |
Chemomab Therapeutics Signals
Chemomab Therapeutics Acquisitions (2)
Chemomab Therapeutics’s most recent deal was a Reverse Merger with Scipher Medicine for . The deal was made on 09-Jul-2026.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Scipher Medicine | 09-Jul-2026 | Reverse Merger | Discovery Tools (Healthcare) | ||
| Anchiano Therapeutics | 16-Mar-2021 | Merger/Acquisition | Drug Discovery |
Chemomab Therapeutics FAQs
-
When was Chemomab Therapeutics founded?
Chemomab Therapeutics was founded in 2011.
-
Where is Chemomab Therapeutics headquartered?
Chemomab Therapeutics is headquartered in Tel Aviv, Israel.
-
What is the size of Chemomab Therapeutics?
Chemomab Therapeutics has 12 total employees.
-
What industry is Chemomab Therapeutics in?
Chemomab Therapeutics’s primary industry is Drug Discovery.
-
Is Chemomab Therapeutics a private or public company?
Chemomab Therapeutics is a Public company.
-
What is Chemomab Therapeutics’s stock symbol?
The ticker symbol for Chemomab Therapeutics is CMMB.
-
What is the current stock price of Chemomab Therapeutics?
As of 18-Nov-2026 the stock price of Chemomab Therapeutics is $1.56.
-
What is the current market cap of Chemomab Therapeutics?
The current market capitalization of Chemomab Therapeutics is $12.5M.
-
What is Chemomab Therapeutics’s annual earnings per share (EPS)?
Chemomab Therapeutics’s EPS for 12 months was -$1.04.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process